INSILICO (03696) clarification: Currently, there is no definite plan for a second listing.
SmartSino (03696) announced that the Board of Directors of the company has noticed recent media reports regarding the company's intention to conduct a secondary listing in Abu Dhabi. The company hereby notifies shareholders and investors that it occasionally considers and evaluates various capital operations after listing, including the feasibility of a secondary listing on other capital markets. However, the company currently does not have any definite plans for a secondary listing. The company will make further announcements in a timely manner according to the Securities Listing Rules of the Stock Exchange of Hong Kong when there are any significant developments.
INSILICO (03696) issued an announcement stating that the board of directors has noticed recent media reports regarding the company's intention to conduct a secondary listing in Abu Dhabi. The company hereby informs shareholders and investors that it regularly considers and evaluates various capital operations after listing, including the feasibility of a secondary listing in other capital markets. However, the company currently does not have any definite plans for a secondary listing. The company will make further announcements in accordance with the rules of the Hong Kong Stock Exchange when there are any significant developments.
Related Articles
Surging more than 79%, oversubscribed more than 3559 times: OLED chip scarcity leader UniPixel Technology (03310) faces revaluation of value.
JINHUI HOLDINGS(00137): Jinhui Shipping first quarter net profit of 4.324 million US dollars decreased by 74.67% year-on-year.
In the first quarter, CSPC Pharma (01093) reported a net profit attributable to shareholders of 860 million yuan, a decrease of 41.8% year-on-year.
Surging more than 79%, oversubscribed more than 3559 times: OLED chip scarcity leader UniPixel Technology (03310) faces revaluation of value.
JINHUI HOLDINGS(00137): Jinhui Shipping first quarter net profit of 4.324 million US dollars decreased by 74.67% year-on-year.
In the first quarter, CSPC Pharma (01093) reported a net profit attributable to shareholders of 860 million yuan, a decrease of 41.8% year-on-year.
